Glioma future or investigational therapies

Jump to navigation Jump to search

Glioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glioma future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glioma future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glioma future or investigational therapies

CDC on Glioma future or investigational therapies

Glioma future or investigational therapies in the news

Blogs on Glioma future or investigational therapies

Directions to Hospitals Treating Glioma

Risk calculators and risk factors for Glioma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Future or Investigational Therapies

  • A small number of low-scale clinical studies have shown possible links between prescription of Carphedon and improvement in a number of encephalopathic conditions, including lesions of cerebral blood pathways and certain types of glioma.
  • American scientists are also studying the effects of Leiurus quinquestriatus scorpion (Israeli Yellow Scorpion) venom on glioma. They have successfully isolated the peptide chlorotoxin from the venom of the L. quinquestriatus scorpion by means of gel filtration chromatography. The peptide appears to target glioma-specific chloride ion channels within the cancerous glial cells of the brain, where it binds with a high affinity.
  • In 2006, German physicians reported on a dose-escalation study for the compound AP 12009 (a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming growth factor TGF-beta2) in patients with high-grade gliomas. At the time of the report, the median overall survival had not been obtained and the authors hinted at a potential cure.
  • As of 2006, additional research started within the past few years is ongoing. Some of the topics included in this research are:
    • efficiency of variations in radiotherapy procedures
    • drugs to stop the growth of tumors by preventing them to develop blood vessels
    • efficiency of combinations of different treatments
    • vaccination therapy.
  • Although there have been individual cases of patients receiving an experimental treatment who still showed no signs of tumor 3 years or even more after the first diagnosis, often a new treatment for GBM will already be considered successful if it significantly increases the percentage of survivors after two years.
  • A cancer vaccine "Oncophage" is currently showing great promise in clinical trails, 2007.

References

  1. Gromeier M, Wimmer E (2001). "Viruses for the treatment of malignant glioma". Curr. Opin. Mol. Ther. 3 (5): 503–8. PMID 11699896.
  2. Rainov N, Ren H (2003). "Gene therapy for human malignant brain tumors". Cancer journal (Sudbury, Mass.). 9 (3): 180–8. PMID 12952303.


Template:WikiDoc Sources